● Recruiting

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Condition: Paroxysmal Nocturnal Haemoglobinuria (PNH) · Sponsor: Wuhan Createrna Science and Technology Co., Ltd

PhasePhase 3

Planned participants66

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.

This description comes directly from the study's public registry record.

Talk to the study team

Wuhan Createrna Science and Technology Co.,Ltd · 027-68788900 · lcyxzx@createrna.com

Always discuss trial participation with your own doctor first.

Locations (2)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences	Beijing, Beijing Municipality, China	Not Yet Recruiting
Chinese Academy of Medical Sciences Hematology Hospital	Tianjin, Tianjin Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06932744